These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18505357)

  • 1. Diagnostic and treatment challenges of chronic fatigue syndrome: role of immediate-release methylphenidate.
    Valdizán Usón JR; Idiazábal Alecha MA
    Expert Rev Neurother; 2008 Jun; 8(6):917-27. PubMed ID: 18505357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does methylphenidate reduce the symptoms of chronic fatigue syndrome?
    Blockmans D; Persoons P; Van Houdenhove B; Bobbaers H
    Am J Med; 2006 Feb; 119(2):167.e23-30. PubMed ID: 16443425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibromylagia, chronic fatigue, and adult attention deficit hyperactivity disorder in the adult: a case study.
    Young JL; Redmond JC
    Psychopharmacol Bull; 2007; 40(1):118-26. PubMed ID: 17285103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of long-acting OROS methylphenidate on routine driving in young adults with attention-deficit/hyperactivity disorder.
    Cox DJ; Mikami AY; Cox BS; Coleman MT; Mahmood A; Sood A; Moore M; Burket R; Merkel RL
    Arch Pediatr Adolesc Med; 2008 Aug; 162(8):793-4. PubMed ID: 18678816
    [No Abstract]   [Full Text] [Related]  

  • 6. Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD.
    Kim Y; Shin MS; Kim JW; Yoo HJ; Cho SC; Kim BN
    Hum Psychopharmacol; 2009 Mar; 24(2):95-102. PubMed ID: 19226534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropsychological performance in persons with chronic fatigue syndrome: results from a population-based study.
    Majer M; Welberg LA; Capuron L; Miller AH; Pagnoni G; Reeves WC
    Psychosom Med; 2008 Sep; 70(7):829-36. PubMed ID: 18606722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate.
    Schwartz AL; Thompson JA; Masood N
    Oncol Nurs Forum; 2002 Aug; 29(7):E85-90. PubMed ID: 12183762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating attention-deficit/hyperactivity disorder with a stimulant transdermal patch: the clinical art.
    Arnold LE; Lindsay RL; López FA; Jacob SE; Biederman J; Findling RL; Ramadan Y
    Pediatrics; 2007 Nov; 120(5):1100-6. PubMed ID: 17974748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal methylphenidate system: old wine in a new bottle.
    Bukstein OG
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):661-5. PubMed ID: 19442029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An approach to chronic fatigue syndrome in adults.
    Sabin TD
    Neurologist; 2003 Jan; 9(1):28-34. PubMed ID: 12801429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropsychological performance and noradrenaline function in chronic fatigue syndrome under conditions of high arousal.
    Morriss RK; Robson MJ; Deakin JF
    Psychopharmacology (Berl); 2002 Sep; 163(2):166-73. PubMed ID: 12202963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relations among body consciousness, somatic symptom report, and information processing speed in chronic fatigue syndrome.
    van der Werf SP; de Vree B; van Der Meer JW; Bleijenberg G
    Neuropsychiatry Neuropsychol Behav Neurol; 2002 Mar; 15(1):2-9. PubMed ID: 11877546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment with methylphenidate in fatigue syndrome].
    Björkhem Bergman L; Böttiger Y
    Lakartidningen; 2010 Nov 17-23; 107(46):2900-1. PubMed ID: 21197788
    [No Abstract]   [Full Text] [Related]  

  • 18. Physician-reported practice of the use of methylphenidate in Japanese palliative care units.
    Matsuo N; Morita T
    J Pain Symptom Manage; 2007 Jun; 33(6):655-6. PubMed ID: 17531905
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
    Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
    Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letter to the editor: Comment on 'Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder'.
    Olders H
    J Pediatr Psychol; 2009; 34(1):108-9; author reply 110-2. PubMed ID: 19136567
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.